Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy.
about
Kinases as druggable targets in trypanosomatid protozoan parasitesTrypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leadsLapatinib-binding protein kinases in the African trypanosome: identification of cellular targets for kinase-directed chemical scaffoldsRegulators of Trypanosoma brucei cell cycle progression and differentiation identified using a kinome-wide RNAi screenA Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3βAssessing the trypanocidal potential of natural and semi-synthetic diketopiperazines from two deep water marine-derived fungi.New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugsAn inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3An essential farnesylated kinesin in Trypanosoma brucei.The design and synthesis of potent and selective inhibitors of Trypanosoma brucei glycogen synthase kinase 3 for the treatment of human african trypanosomiasis.In vivo anthelmintic effect of flavonol rhamnosides from Dryopteris crassirhizoma against Dactylogyrus intermedius in goldfish (Carassius auratus).Locating sweet spots for screening hits and evaluating pan-assay interference filters from the performance analysis of two lead-like librariesStructure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3.From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules.Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in MiceThree-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future.AAK1 identified as an inhibitor of neuregulin-1/ErbB4-dependent neurotrophic factor signaling using integrative chemical genomics and proteomics.Chemical proteomic analysis reveals the drugability of the kinome of Trypanosoma brucei.Induced resistance to methionyl-tRNA synthetase inhibitors in Trypanosoma brucei is due to overexpression of the target.Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei [corrected].Glycogen Synthase Kinase 3β Promotes the Endocytosis of Transferrin in the African TrypanosomeState of the art in African trypanosome drug discovery.Development of novel drugs for human African trypanosomiasis.Dihydrofolate reductase as a therapeutic target for infectious diseases: opportunities and challenges.Drug discovery and human African trypanosomiasis: a disease less neglected?Enzyme Activity Assays for Protein Kinases: Strategies to Identify Active Substrates.Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases.First computational chemistry multi-target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines.Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.High throughput screening against the peroxidase cascade of African trypanosomes identifies antiparasitic compounds that inactivate tryparedoxin.Identification of a RAC/AKT-like gene in Leishmania parasites as a putative therapeutic target in leishmaniasis.Bioinformatic analysis of glycogen synthase kinase 3: human versus parasite kinases.Rational Selection of Anti-Microbial Drug Targets: Unique or Conserved?
P2860
Q26786761-A4B20090-3CD1-4CAE-8434-741EA09C6BBBQ28477646-95CC856D-82E9-46CD-999F-5F0F84E42143Q28486270-BBE5D1A6-60B2-4A54-98D9-C15F4CDD90E7Q28538804-FA762E9C-147D-4AD9-85B0-59B397250812Q28550557-5524EB18-14FD-400D-92DD-BC3843694E6FQ33543529-B15DA4AE-7399-4A5C-89D3-A7B0D6759129Q33622982-7DAB9032-FED1-457F-80F9-9C46BD7BF368Q33688195-56BE911A-87A4-4271-80EE-C39E33E79CC3Q34071572-D6879CFE-CF55-4430-AD19-FE493AF1EBA3Q34243232-DE4C5C73-1FB8-40D8-8693-1DCA2D451632Q34369358-CCB200FC-8DAF-4005-AF02-3F7371A30FB4Q34604133-FFF1F317-74F6-42E2-93A3-9F31B29AEBF8Q34608978-4E0A4670-6A7D-4614-B74C-DA11D8CC0A31Q34775438-EE549EA3-9EA1-4F50-A7FF-706B056D31F8Q34933050-0DE14D6B-CF34-48D0-A9C9-B11E74396087Q35592514-7ACE2B14-32F5-4243-ACE5-85E109655876Q36012247-713E70A6-0EC5-4BE6-A5D8-CF778531FBC2Q36753140-E8ADD1E2-8357-4E37-9E56-3BB267CDCC17Q36969804-A3544397-EAA8-4412-B2B6-C17206BEFCCBQ36998826-65803CB0-6964-4D3B-ABD4-6EB6AF8C02ADQ37259836-4CD39E44-1252-466D-B3EE-D75190FD2E56Q37852737-24085A14-B1DA-4497-89E8-0C055FBB856FQ37894699-22A0065A-79AA-4A2B-BD2A-34C5C42B8909Q38026606-C028A79C-2FDB-463F-8C85-003EB1FB69C8Q38154344-39601AA9-2956-4A79-BD21-DD323BA78451Q38697065-10EAC436-4D76-4C95-A55D-0AE4FCBB683CQ38972808-2164AD29-959A-43DE-AFBF-29321AA1B11DQ39646871-E3BCF953-389E-4BC0-8E42-258B9A1D9760Q40306944-BCBC5472-19DF-442A-A8A2-5019655AFD2EQ42058134-70A2419F-3117-49CC-B30F-BF49121D7416Q42373534-58085507-0AD4-49A6-8179-D7C9F03795ECQ45241478-3B1DD9C4-EC82-4E9B-AD2C-D29BA0FA51EBQ58850854-557BD343-8FFC-4C82-BA57-F5339C368C36
P2860
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Glycogen synthase kinase 3 is ...... rican trypanosomiasis therapy.
@en
type
label
Glycogen synthase kinase 3 is ...... rican trypanosomiasis therapy.
@en
prefLabel
Glycogen synthase kinase 3 is ...... rican trypanosomiasis therapy.
@en
P2093
P2860
P921
P356
P1476
Glycogen synthase kinase 3 is ...... rican trypanosomiasis therapy.
@en
P2093
Aaron J Riechers
Alberto J Napuli
Alexander Scheer
Christophe L M J Verlinde
Frederick S Buckner
J Robert Gillespie
Kayode K Ojo
Mathias M Domostoj
Susan J Wells
Wesley C Van Voorhis
P2860
P304
P356
10.1128/AAC.00364-08
P407
P577
2008-07-21T00:00:00Z